Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
Fig 6
Her2-bridging CAR-CD19 T cells eliminate Her2-positive tumors and CD19-positive tumors in a serial challenge in vivo model.
A-C) CAR T cells (donor 45, 99.2% CD3-positive, 45% CD8-positive, 34% Flag-tag-positive) were evaluated in a SKOV3 ovarian carcinoma model in NSG mice. A) CAR-374 treatment eliminated preestablished SKOV3 tumors in the NSG mouse model. B) 90% of CAR-374 treated mice survived past day 36, by which point the control mice were beginning to require euthanasia. C) CAR-374 that survived the SKOV3 challenge subsequently cleared CD19-positive Nalm6 leukemia challenge; all individual mice are shown. * = p < 0.001.